

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	<b>MAIL STOP AMENDMENT</b>
Nicholas Bodor et al.	)	
	)	Group Art Unit: 1623
Application No.: 10/551,205	)	
	)	Examiner: JONATHAN S LAU
Filed: November 14, 2006	)	
	)	Confirmation No.: 4092
For: ORAL FORMULATIONS OF	)	
CLADRIBINE	)	

**REPLY AND AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated April 4, 2008, please first amend the above-identified patent application as follows: